{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:26:59Z","timestamp":1792718819000,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T00:00:00Z","timestamp":1667088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T00:00:00Z","timestamp":1667088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1038\/s41375-022-01740-9","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T02:02:40Z","timestamp":1667095360000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"37","author":[{"given":"Valeria","family":"Ceolin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Brivio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"van Tinteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan R.","family":"Rheingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Leahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Vormoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9054-4321","authenticated-orcid":false,"given":"Maureen M.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Kalwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2449-539X","authenticated-orcid":false,"given":"Barbara","family":"De Moerloose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-8942","authenticated-orcid":false,"given":"Elad","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-0265","authenticated-orcid":false,"given":"Peter","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8134-9682","authenticated-orcid":false,"given":"M\u00f3nica","family":"L\u00f3pez-Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-3228","authenticated-orcid":false,"given":"Bianca F.","family":"Goemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hoogerbrugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-0929","authenticated-orcid":false,"given":"Friso G.","family":"Calkoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-8268","authenticated-orcid":false,"given":"Christian Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,30]]},"reference":[{"key":"1740_CR1","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524\u201339.","journal-title":"Haematologica"},{"key":"1740_CR2","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1200\/JCO.2012.48.5680","volume":"31","author":"C Eckert","year":"2013","unstructured":"Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Gr\u00fcmayer R, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. 2013;31:2736\u201342.","journal-title":"J Clin Oncol"},{"key":"1740_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejca.2021.03.034","volume":"151","author":"C Eckert","year":"2021","unstructured":"Eckert C, Parker C, Moorman AV, Irving JA, Kirschner-Schwabe R, Groeneveld-Krentz S, et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021;151:175\u201389.","journal-title":"Eur J Cancer"},{"key":"1740_CR4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/13543784.2021.1916466","volume":"30","author":"JM Asare","year":"2021","unstructured":"Asare JM, Rabik CA, Muller B, Brown PA, Cooper S. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients. Expert Opin Investig Drugs. 2021;30:611\u201320.","journal-title":"Expert Opin Investig Drugs"},{"key":"1740_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740\u201353.","journal-title":"N Engl J Med"},{"key":"1740_CR6","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1182\/blood.2020007848","volume":"137","author":"E Brivio","year":"2021","unstructured":"Brivio E, Locatelli F, Lopez-Yurda M, Malone A, D\u00edaz-de-Heredia C, Bielorai B, et al. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood. 2021;137:1582\u201390.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1740_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1182\/blood-2020-134774","volume":"136","author":"E Brivio","year":"2020","unstructured":"Brivio E, Locatelli F, Thano A, Petit A, Vormoor BJ, Rives S. et al. A phase II study of single-agent inotuzumab ozogamicin in pediatric CD22-positive relapsed\/refractory acute lymphoblastic leukemia: results of the ITCC-059 study. Blood. 2020;136(Supplement 1):8\u20139.","journal-title":"Blood"},{"key":"1740_CR8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.21.01693","volume":"40","author":"MM O\u2019Brien","year":"2022","unstructured":"O\u2019Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, et al. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Protocol AALL1621. J Clin Oncol. 2022;40:956\u201367.","journal-title":"J Clin Oncol"},{"issue":"Supplement_1","key":"1740_CR9","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1182\/blood-2019-129279","volume":"134","author":"S Grupp","year":"2019","unstructured":"Grupp S, Hu Z-H, Zhang Y, Keating A, Pulsipher MA, Philips C. et al. Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory children and young adults with acute lymphoblastic leukemia (ALL): real world experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry. Blood. 2019;134(Supplement_1):2619.","journal-title":"Blood"},{"key":"1740_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"1740_CR11","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322\u201331.","journal-title":"Blood"},{"key":"1740_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328.","journal-title":"Lancet"},{"key":"1740_CR13","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood.2019001641","volume":"134","author":"KJ Curran","year":"2019","unstructured":"Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N. et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood. 2019;134:2361\u20138. Blood. 2020;136:1374.","journal-title":"Blood"},{"key":"1740_CR14","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4:5414\u201324.","journal-title":"Blood Adv"},{"key":"1740_CR15","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021;39:1650\u20139.","journal-title":"J Clin Oncol"},{"key":"1740_CR16","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1200\/JCO.20.02477","volume":"39","author":"S Kadauke","year":"2021","unstructured":"Kadauke S, Myers RM, Li Y, Aplenc R, Baniewicz D, Barrett DM, et al. Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial. J Clin Oncol. 2021;39:920\u201330.","journal-title":"J Clin Oncol"},{"key":"1740_CR17","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med"},{"key":"1740_CR18","doi-asserted-by":"crossref","unstructured":"Rives S, Maude SL, Hiramatsu H, Baruchel A, Bader P, Bittencourt H, et al. Tisagenlecleucel in pediatric and young adult patients (PTS) with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL): final analyses from the Eliana Study. EHA Library 2022;S112:356977.","DOI":"10.1097\/01.HS9.0000843344.19780.98"},{"key":"1740_CR19","doi-asserted-by":"crossref","unstructured":"Dourthe ME, Rabian F, Yakouben K, Chevillon F, Cabannes-Hamy A, Mechinaud F, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. 2021;35:3383\u201393.","DOI":"10.1038\/s41375-021-01281-7"},{"key":"1740_CR20","doi-asserted-by":"crossref","unstructured":"Barz Leahy A, Devine KJ, Li Y, Liu H, Myers RM, DiNofia A, et al. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T cell therapy. Blood. 2022;139:2173\u201385.","DOI":"10.1182\/blood.2021012727"},{"key":"1740_CR21","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","volume":"3","author":"V Pillai","year":"2019","unstructured":"Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3:3539\u201349.","journal-title":"Blood Adv"},{"key":"1740_CR22","doi-asserted-by":"crossref","unstructured":"Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022;40:932\u201344.","DOI":"10.1200\/JCO.21.01405"},{"key":"1740_CR23","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381\u20139.","journal-title":"J Clin Oncol"},{"key":"1740_CR24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","volume":"33","author":"D Bhojwani","year":"2019","unstructured":"Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, et al. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2019;33:884\u201392.","journal-title":"Leukemia"},{"issue":"Supplement_1","key":"1740_CR25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1182\/blood-2019-128977","volume":"134","author":"MM O\u2019Brien","year":"2019","unstructured":"O\u2019Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yi JS. et al. A Phase 2 trial of inotuzumab ozogamicin (InO) in children and young adults with relapsed or refractory (R\/R) CD22+ B-acute lymphoblastic leukemia (B-ALL): results from Children\u2019s Oncology Group Protocol AALL1621. Blood. 2019;134(Supplement_1):741.","journal-title":"Blood"},{"issue":"suppl","key":"1740_CR26","doi-asserted-by":"publisher","first-page":"10518","DOI":"10.1200\/JCO.2020.38.15_suppl.10518","volume":"38","author":"J Krueger","year":"2020","unstructured":"Krueger J, Bittencourt HNS, Rives S, Baruchel A, Moerloose BD, Peters C. et al. Tisagenlecleucel (Tisa) for relapsed\/refractory (r\/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO). J Clin Oncol. 2020;38(suppl):10518.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1740_CR27","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1182\/blood-2021-148820","volume":"138","author":"K Mullanfiroze","year":"2021","unstructured":"Mullanfiroze K, Ottaviano G, Mishra AK, Gabelli M, Lazareva A, Burridge S. et al. Outcomes of children and young adults with acute lymphoblastic leukaemia administered inotuzumab pre CAR-T therapy. Blood. 2021;138(Supplement 1):1743.","journal-title":"Blood"},{"key":"1740_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10928-018-9614-9","volume":"46","author":"M Garrett","year":"2019","unstructured":"Garrett M, Ruiz-Garcia A, Parivar K, Hee B, Boni J. Population pharmacokinetics of inotuzumab ozogamicin in relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. J Pharmacokinet Pharmacodyn. 2019;46:211\u201322.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"Supplement 1","key":"1740_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood-2020-134472","volume":"136","author":"LM Schultz","year":"2020","unstructured":"Schultz LM, Baggott C, Prabhu S, Pacenta H, Phillips CL, Rossoff J. et al. Disease burden impacts outcomes in pediatric and young adult B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel: results from the Pediatric Real World CAR Consortium (PRWCC). Blood. 2020;136(Supplement 1):14\u20135.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01740-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01740-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01740-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T06:06:01Z","timestamp":1674799561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01740-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,30]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1740"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01740-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,30]]},"assertion":[{"value":"9 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SRR: honoraria and research funding Pfizer and Jazz. MMO: honoraria and research funding Pfizer and Jazz. BDM: advisory board Novartis, travel funding Jazz. EJ: honoraria and membership on an entity\u2019s Board of Directors or advisory committees Novartis. FL: honoraria for speakers\u2019 bureau or participation in advisory boards from Amgen, Bellicum Pharmaceutical, Celgene, Jazz Pharmaceutical, Miltenyi, Sanofi and Novartis. PH: honoraria for lectures, consultancy and\/or scientific advisory boards from Novartis and BMS. CMZ: consultancy Sanofi, Novartis, Roche, Incyte, travel funding and research funding Jazz, research funding BMS, AbbVie, Kura oncology, Takeda, Pfizer. Other authors have no COI to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}